LSE:GSKPharmaceuticals
GSK Buys 35Pharma As Pulmonary Hypertension Bet Fuels Valuation Debate
GSK agreed to acquire Canadian biotech 35Pharma for about US$950m.
The deal brings HS235, an investigational therapy for pulmonary hypertension and related metabolic issues, into GSK's cardiopulmonary pipeline.
The transaction aims to expand GSK's respiratory, immunology, and inflammation portfolio within specialty medicines.
LSE:GSK is adding 35Pharma at a time when its share price stands at £22.01, with returns of 20.2% year to date and 56.2% over the past year. Over three and five years,...